CLVS Clovis Oncology Inc

Price (delayed)

$6.68

Market cap

$589.97M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.24

Enterprise value

$1B

Sector: Healthcare
Industry: Biotechnology

Highlights

CLVS's EPS is up by 30% YoY and by 14% from the previous quarter
Clovis Oncology's revenue has increased by 20% YoY
Clovis Oncology's debt has decreased by 9% YoY but it has increased by 3.1% from the previous quarter
The equity has plunged by 87% YoY and by 68% from the previous quarter
The quick ratio has contracted by 41% YoY and by 20% from the previous quarter

Key stats

What are the main financial stats of CLVS
Market
Shares outstanding
88.32M
Market cap
$589.97M
Enterprise value
$1B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.23
Earnings
Revenue
$160.53M
EBIT
-$337.51M
EBITDA
-$329.33M
Free cash flow
-$267.32M
Per share
EPS
-$5.24
Free cash flow per share
-$3.03
Book value per share
-$1.85
Revenue per share
$1.82
TBVPS
$5.24
Balance sheet
Total assets
$593.06M
Total liabilities
$756.42M
Debt
$635.01M
Equity
-$163.37M
Working capital
$165.32M
Liquidity
Debt to equity
-3.89
Current ratio
2.33
Quick ratio
1.98
Net debt/EBITDA
-1.25
Margins
EBITDA margin
-205.1%
Gross margin
75.3%
Net margin
-230.3%
Operating margin
-204.9%
Efficiency
Return on assets
-59.3%
Return on equity
N/A
Return on invested capital
-41.5%
Return on capital employed
-71.9%
Return on sales
-210.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLVS stock price

How has the Clovis Oncology stock price performed over time
Intraday
4.7%
1 week
19.71%
1 month
33.07%
1 year
-26.91%
YTD
39.17%
QTD
39.17%

Financial performance

How have Clovis Oncology's revenue and profit performed over time
Revenue
$160.53M
Gross profit
$120.89M
Operating income
-$328.87M
Net income
-$369.76M
Gross margin
75.3%
Net margin
-230.3%
The operating margin has grown by 28% YoY and by 10% from the previous quarter
Clovis Oncology's net margin has increased by 23% YoY and by 4.7% from the previous quarter
Clovis Oncology's revenue has increased by 20% YoY
CLVS's gross profit is up by 19% year-on-year

Growth

What is Clovis Oncology's growth rate over time

Valuation

What is Clovis Oncology stock price valuation
P/E
N/A
P/B
N/A
P/S
3.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.23
CLVS's EPS is up by 30% YoY and by 14% from the previous quarter
The equity has plunged by 87% YoY and by 68% from the previous quarter
CLVS's P/S is 100% below its 5-year quarterly average of 1424.8 but 8% above its last 4 quarters average of 3.4
Clovis Oncology's revenue has increased by 20% YoY

Efficiency

How efficient is Clovis Oncology business performance
CLVS's ROS is up by 27% YoY and by 6% from the previous quarter
The company's return on assets fell by 13% YoY
Clovis Oncology's return on invested capital has decreased by 6% YoY

Dividends

What is CLVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLVS.

Financial health

How did Clovis Oncology financials performed over time
The company's total assets is 22% lower than its total liabilities
The quick ratio has contracted by 41% YoY and by 20% from the previous quarter
The current ratio has contracted by 38% YoY and by 19% from the previous quarter
The equity has plunged by 87% YoY and by 68% from the previous quarter
The company's debt to equity has surged by 51% YoY and by 39% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.